Abstract
The maximum tolerated dose for a combination chemotherapy regimen of Thiotepa, Mitoxantrone and Methotrexate (TMM) administered intravenously every three weeks to twelve patients with metastatic breast cancer was: Thiotepa: 15mg/m2, Mitoxantrone: 10mg/m2 and Methotrexate: 30mg/m2. The major toxicities from the combination related to myelosuppression. Partial response was seen in 5 patients, ranging in duration from 1.25 to 10 months. Four out of eight patients who had received prior doxorubicin responded. The results are encouraging and warrant further study of this combination.
| Original language | English |
|---|---|
| Pages (from-to) | 443-444 |
| Number of pages | 2 |
| Journal | Annals of Oncology |
| Volume | 1 |
| Issue number | 6 |
| DOIs | |
| State | Published - Nov 1990 |
Keywords
- Combination chemotherapy
- Metastatic breast cancer
- Mitoxantrone and Methotrexate
- TMM
- Thiotepa